The field of single-cell analysis has advanced rapidly in the last decade and is providing
new insights into the characterization of intercellular genetic heterogeneity and complexity …

The highly heterogenous nature of colorectal cancer can significantly hinder its early and
accurate diagnosis, eventually contributing to high mortality rates. The adenoma-carcinoma …

Background BRAF mutation occurs in 5%–10% of metastatic colorectal cancers (mCRCs).
Patients with BRAF mutant mCRC exhibit a specific metastatic pattern and poor prognosis …

Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. In
terms of overall mortality, it ranks second due to, among other factors, problems with …

Colorectal cancer (CRC), a common malignant tumour of the gastrointestinal tract, is a life-
threatening cancer worldwide. Mutations in KRAS and BRAF, the major driver mutation …

Anti-EGFR targeting is one of the key strategies in the treatment of metastatic colorectal
cancer (mCRC). For almost two decades oncologists have struggled to implement EGFR …

The last two decades have witnessed major breakthroughs in the development of targeted
therapy for patients with metastatic colorectal cancer (mCRC), an achievement which stems …

Abstract BRAF V600E attracts wide attention in the treatment of colorectal cancer (CRC) as
stratifying and predicting a refractory classification of CRC. Recent evidence indicates that …

Immunotherapy has remained at the vanguard of promising cancer therapeutic regimens
due to its exceptionally high specificity for tumor cells and potential for significantly improved …

Abstract Erdheim Chester Disease (ECD) is a rare histiocytic disorder marked by infiltration
of organs with CD68+ histiocytes. ECD stems from mutations of BRAF and MAP2K1 in …